AssetMark’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
Other funds holding FULC
AssetMark's FULC Position: Q3 2026 in Review
AssetMark reduced its Fulcrum Therapeutics (FULC) stake by 20% in Q3 2026, selling an estimated $5.58K and leaving 5,833 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2223.
AssetMark first reported a position in FULC in Q3 2025 and has held it in 5 quarters since. The position peaked at $92.6K in Q4 2025. 99 funds tracked by Wall St. Rank hold FULC as of Q3 2026.
- AssetMark held 5,833 shares of Fulcrum Therapeutics worth $21.6K as of Q3 2026.
- AssetMark sold 1,488 Fulcrum Therapeutics shares in Q3 2026, an estimated $5.58K.
- Fulcrum Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2223 holding.
- AssetMark first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 5 quarters since.
- AssetMark's Fulcrum Therapeutics position peaked at $92.6K in Q4 2025.
- 99 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.